18766 Federal Register / Vol. 76, No. 65 / Tuesday, April 5, 2011 / Notices 

conduct of research, demonstration 

projects, and evaluations with respect to 

health care; (2) in the fields of health 

care quality research or health care 

improvement; (3) in the practice of 

medicine; (4) in other health 

professions; (5) in representing the 

private health care sector (including 

health plans, providers, and purchasers) 

or administrators of health care delivery 

systems; (6) in the fields of health care 

economics, information systems, law, 

ethics, business, or public policy; and, 

(7) in representing the interests of 

patients and consumers of health care. 

42 U.S.C. 299c(c)(2). Individuals are 

particularly sought with experience and 

success in activities specified in the 

summary above. 

DATES: Nominations should be received 

on or before 60 days after date of 

publication. 

ADDRESSES: Nominations should be sent 

to Ms. Karen Brooks, AHRQ, 540 

Gaither Road, Room 3006, Rockville, 

Maryland 20850. Nominations may also 

be e-mailed to 

Karen.Brooks@ahrq.hhs.gov. 

FOR FURTHER INFORMATION CONTACT: Ms. 

Karen Brooks, AHRQ, at (301) 427– 

1801. 

SUPPLEMENTARY INFORMATION: 42 U.S.C. 

299c provides that the Secretary shall 

appoint to the National Advisory 

Council for Healthcare Research and 

Quality twenty one appropriately 

qualified individuals. At least seventeen 

members shall be representatives of the 

public and at least one member shall be 

a specialist in the rural aspects of one 

or more of the professions or fields 

listed in the above summary. In 

addition, the Secretary designates, as ex 

officio members, representatives from 

other Federal agencies, principally 

agencies that conduct or support health 

care research, as well as Federal officials 

the Secretary may consider appropriate. 

42 U.S.C. 299c(c)(3). The Council meets 

in the Washington, DC, metropolitan 

area, generally in Rockville, Maryland, 

approximately three times a year to 

provide broad guidance to the Secretary 

and AHRQ’s Director on the direction of 

and programs undertaken by AHRQ. 

Seven individuals will be selected 

presently by the Secretary to serve on 

the Council beginning with the meeting 

in the spring of 2012. Members 

generally serve 3-year terms. 

Appointments are staggered to permit 

an orderly rotation of membership. 

Interested persons may nominate one 

or more qualified persons for 

membership on the Council. Selfnominations are accepted. Nominations 

shall include: (1) A copy of the 

nominee’s resume or curriculum vitae; 

and (2) a statement that the nominee is 

willing to serve as a member of the 

Council. Selected candidates will be 

asked to provide detailed information 

concerning their financial interests, 

consultant positions and research grants 

and contracts, to permit evaluation of 

possible sources of conflict of interest. 

Please note that Federally registered 

lobbyists are not permitted to serve on 

this advisory board. Please note that 

once you are nominated, AHRQ may 

consider your nomination for future 

positions on the Council. 

The Department seeks a broad 

geographic representation. In addition, 

AHRQ conducts and supports research 

concerning priority populations, which 

include: low-income groups; minority 

groups; women; children; the elderly; 

and individuals with special health care 

needs, including individuals with 

disabilities and individuals who need 

chronic care or end-of-life health care. 

See 42 U.S.C. 299(c). Nominations with 

expertise in health care for these 

priority populations are encouraged. 

Dated: March 24, 2011. 

Carolyn M. Clancy, 

Director. 

[FR Doc. 2011–8023 Filed 4–4–11; 8:45 am] 

BILLING CODE 4160–90–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Disease, Disability, and Injury 

Prevention and Control Special 

Emphasis Panel (SEP): Initial Review 

The meeting announced below 

concerns Epidemiologic Research and 

Surveillance in Epilepsy, Funding 

Opportunity Announcement (FOA) 

DP11–003, initial review. 

In accordance with Section 10(a)(2) of 

the Federal Advisory Committee Act 

(Pub. L. 92–463), the Centers for Disease 

Control and Prevention (CDC) 

announces the aforementioned meeting: 

Time and Date: 11 a.m.–5 p.m., May 11, 

2011 (Closed). 

Place: Teleconference. 

Status: The meeting will be closed to the 

public in accordance with provisions set 

forth in Section 552b(c)(4) and (6), Title 5 

U.S.C., and the Determination of the Director, 

Management Analysis and Services Office, 

CDC, pursuant to Public Law 92–463. 

Matters to be Discussed: The meeting will 

include the initial review, discussion, and 

evaluation of applications received in 

response to ‘‘Epidemiologic Research and 

Surveillance in Epilepsy FOA DP11–003, 

initial review.’’ 

Contact Person for More Information: 

Brenda Colley Gilbert, PhD, M.P.H., Director, 

Extramural Research Program Office, 

National Center for Chronic Disease 

Prevention and Developmental Disabilities, 

CDC, 1600 Clifton Road, NE., Mailstop K92, 

Atlanta, Georgia 30333, Telephone: (770) 

488–6295. 

The Director, Management Analysis and 

Services Office, has been delegated the 

authority to sign Federal Register notices 

pertaining to announcements of meetings and 

other committee management activities, for 

both the Centers for Disease Control and 

Prevention and the Agency for Toxic 

Substances and Disease Registry. 

Dated: March 29, 2011. 

Elaine L. Baker, 

Director, Management Analysis and Services 

Office, Centers for Disease Control and 

Prevention. 

[FR Doc. 2011–8071 Filed 4–4–11; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Medicare & Medicaid 

Services 

[CMS–9996–N] 

Early Retiree Reinsurance Program 

AGENCY: Centers for Medicare & 

Medicaid Services (CMS), HHS. 

ACTION: Notice. 

SUMMARY: This notice announces that 

CMS is exercising its authority under 

section 1102(f) of the Affordable Care 

Act to stop accepting applications for 

the Early Retiree Reinsurance Program, 

due to the availability of funds, as of 

May 5, 2011. 

DATES: Effective Date: This notice is 

effective March 31, 2011. 

FOR FURTHER INFORMATION CONTACT: 

David Mlawsky, (410) 786–6851. 

SUPPLEMENTARY INFORMATION: 

I. Background 

The Patient Protection and Affordable 

Care Act (Pub. L. 111–148, enacted on 

March 23, 2010) (the Affordable Care 

Act), included a provision that 

establishes the temporary Early Retiree 

Reinsurance Program (ERRP), which 

provides reimbursement to eligible 

sponsors of employment-based plans for 

a portion of the costs of providing 

health coverage to early retirees (and 

eligible spouses, surviving spouses, and 

dependents of such retirees). Section 

1102(a)(1) of the Affordable Care Act, 

which is codified at 42 U.S.C. 

18002(a)(1), requires the Secretary to 

establish the program within 90 days of 

enactment of the law (by June 21, 2010). 

On May 5, 2010, we published an 


srobinson on DSKHWCL6B1PROD with NOTICES
Federal Register / Vol. 76, No. 65 / Tuesday, April 5, 2011 / Notices 18767 

interim final regulation with comment 

period in the Federal Register (75 FR 

24450), implementing the program as of 

June 1, 2010. Section 1102(e) of the 

Affordable Care Act appropriates 

funding of $5 billion for the temporary 

program, which ends no later than 

January 1, 2014. To participate in the 

program, an employment-based plan 

must submit an application to the 

Secretary. A copy of the application can 

be found at http://www.errp.gov. Section 

1102(f) of the Affordable Care Act grants 

the Secretary the authority to stop 

taking applications for participation in 

the program based on the availability of 

funding under section 1102(e) of the 

Affordable Care Act. The ERRP interim 

final regulation also grants the Secretary 

such authority (75 FR 24456). 

II. Provisions of the Notice 

Based on the amount of the $5 billion 

in appropriated program funding that 

remains available and the rate at which 

it is being disbursed, we are 

announcing, under section 1102(f) of the 

Affordable Care Act, that we will no 

longer accept applications for the 

program after May 5, 2011. We have 

projected the availability of program 

funding based on the rate at which 

appropriated funds are currently being 

used to reimburse plan sponsors, and 

we have concluded that we have 

approved a sufficient number of 

applications to exhaust the program 

funding. Applications were first 

accepted by the ERRP on June 29, 2010, 

and therefore, plan sponsors have so far 

had 9 months to submit applications if 

desired. As a result of this agency 

action, any program applications that 

CMS receives after May 5, 2011 will not 

be accepted for processing. Applications 

must be received in the program’s Intake 

Center on or before May 5, 2011, to be 

accepted for processing. A copy of the 

application, as well as information on 

how to complete and send it, and where 

to send it, can be found on http:// 

www.errp.gov. Merely postmarking an 

application before this date will not be 

sufficient. We will post additional 

information about the mechanics of not 

accepting such applications for 

processing, such as how we will 

respond upon receiving such an 

application, on http://www.errp.gov. 

We note that our decision to no longer 

accept applications after May 5, 2011, is 

based on the actual availability of 

remaining appropriated ERRP funds and 

the rate at which we have been 

disbursing reimbursement, as opposed 

to the projected amounts of ERRP 

reimbursements that applicants listed in 

their ERRP applications. Should 

circumstances related to the availability 

of ERRP funding change, we may decide 

it is appropriate to resume accepting 

ERRP applications. If this occurs, we 

will provide such notice in the Federal 

Register. 

III. Collection of Information 

Requirements 

This document does not impose 

information collection and 

recordkeeping requirements. So, it need 

not be reviewed by the Office of 

Management and Budget under the 

authority of the Paperwork Reduction 

Act of 1995. 

Authority: 42 U.S.C. 18002(f). 

Dated: March 29, 2011. 

Donald M. Berwick, 

Administrator, Centers for Medicare & 

Medicaid Services. 

[FR Doc. 2011–7934 Filed 3–31–11; 4:15 pm] 

BILLING CODE 4120–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Food and Drug Administration 

[Docket No. FDA–2011–N–0002] 

Preparation for International 

Cooperation on Cosmetics 

Regulations; Public Meeting 

AGENCY: Food and Drug Administration, 

HHS. 

ACTION: Notice of public meeting. 

SUMMARY: The Food and Drug 

Administration (FDA) is announcing a 

public meeting entitled ‘‘International 

Cooperation on Cosmetics Regulations 

(ICCR)—Preparation for ICCR–5 Meeting 

in Paris, France’’ to provide information 

and receive comments on the 

International Cooperation on Cosmetics 

Regulations (ICCR) as well as the 

upcoming meetings in Paris, France. 

The topics to be discussed are the topics 

for discussion at the forthcoming ICCR 

Steering Committee meeting. The 

purpose of the meeting is to solicit 

public input prior to the next steering 

committee and expert working group 

meetings in Paris, France scheduled on 

June 28 through July 1, 2011. 

DATES: Date and Time: The public 

meeting will be held on April 26, 2011, 

from 2 p.m. to 4 p.m. 

Location: The public meeting will be 

held at the Washington Theater room at 

the Hilton Washington DC/Rockville 

Hotel & Executive Meeting Center, 1750 

Rockville Pike, Rockville, MD 20852. 

Contact Person: All participants must 

register with Kimberly Franklin, Office 

of the Commissioner, Food and Drug 

Administration, 10903 New Hampshire 

Ave., Silver Spring, MD 20993–0002, email: Kimberly.Franklin@fda.hhs.gov, or 

Fax: 301–595–7937. 

Registration and Requests for Oral 

Presentations: Send registration 

information (including name, title, firm 

name, address, telephone, and fax 

number), written material, and requests 

to make oral presentations, to the 

contact person by April 22, 2011. 

If you need special accommodations 

due to a disability, please contact 

Kimberly Franklin (see Contact Person) 

at least 7 days in advance. 

Interested persons may present data, 

information, or views orally or in 

writing, on issues pending at the public 

meeting. Time allotted for oral 

presentations may be limited to 10 

minutes. Those desiring to make oral 

presentations should notify the contact 

person by April 22, 2011, and submit a 

brief statement of the general nature of 

the evidence or arguments they wish to 

present, the names and addresses, 

telephone number, fax, and e-mail of 

proposed participants, and an 

indication of the approximate time 

requested to make their presentation. 

Transcripts: Please be advised that as 

soon as a transcript is available, it will 

be accessible at http:// 

www.regulations.gov. It may be viewed 

at the Division of Dockets Management 

(HFA–305), Food and Drug 

Administration, 5630 Fishers Lane, rm. 

1061, Rockville, MD. A transcript will 

also be available in either hardcopy or 

on CD–ROM, after submission of a 

Freedom of Information request. Written 

requests are to be sent to Division of 

Freedom of Information, 12420 

Parklawn Dr., Rockville, MD 20857. 

SUPPLEMENTARY INFORMATION: The 

purpose of the multilateral framework 

on the ICCR is to pave the way for the 

removal of regulatory obstacles to 

international trade while maintaining 

global consumer protection. 

ICCR is a voluntary international 

group of cosmetics regulatory 

authorities from the United States, 

Japan, the European Union, and Canada. 

These regulatory authority members 

will enter into constructive dialogue 

with their relevant cosmetics’ industry 

trade associations. Currently, the ICCR 

members are Health Canada; the 

European Directorate General for 

Enterprise and Industry; the Ministry of 

Health, Labor and Welfare of Japan; and 

the U.S. Food and Drug Administration. 

All decisions made by the consensus 

will be compatible with the laws, 

policies, rules, regulations, and 

directives of the respective 

administrations and governments. 

Members will implement and/or 


srobinson on DSKHWCL6B1PROD with NOTICES